Block Listing Six Monthly Return

Spectral MD Holdings, Ltd.

01 June 2023

 

Spectral MD Holdings, Ltd

        ("Spectral MD" or the "Company")                        

Block Listing Six Monthly Return

LONDON, U.K. AND DALLAS, TX, U.S -Spectral MD Holdings, Ltd. (AIM: SMD), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, provides the following information in connection with its block admissions pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies:

Name of applicant:		Spectral MD Holdings, Ltd.
Name of scheme:		2018 Long-Term Incentive Plan
Period of return:	From:	8 November 2022	To:	7 May 2023
Balance of unallotted securities under scheme(s) from previous return:		2,000,000 Ordinary shares
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		-
Less:  Number of securities issued/allotted under scheme(s) during period:		104,451 Ordinary shares
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		1,895,549 Ordinary shares

Name of contact:	Vince Capone, General Counsel/Corporate Secretary
Telephone number of contact:	[phone]

For further information please contact:

Spectral MD Holdings, Ltd.
Wensheng Fan, Chief Executive Officer Nils Windler, Chief Financial Officer	[e-mail] via Walbrook PR
SP Angel Corporate Finance LLP (NOMAD and Joint Broker for Spectral MD)
Stuart Gledhill / Harry Davies-Ball (Corporate Finance) Vadim Alexandre / Rob Rees (Sales & Broking)	Tel: [phone]
The Equity Group Inc. (US Investor Relations)
Devin Sullivan	[e-mail] Tel: [phone]
Walbrook PR Ltd (UK Media & Investor Relations)
Paul McManus / Louis Ashe-Jepson /Alice Woodings	[e-mail] Tel: [phone]

About Spectral MD

Spectral MD is a predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care for burn, DFU, and future clinical applications. At Spectral MD, we are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown"® with our DeepView® Wound Diagnostics System. The Company's DeepView® platform is the only predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results that substantially exceed the current standard of care, Spectral MD's diagnostic platform is expected to provide faster and more accurate treatment insight, significantly improving patient care and clinical outcomes. For more information, visit the Company at: www.spectralmd.com

 

END